Please assess the completion status of the following clinical trial:

Trial Title: Etanercept Treatment in the Early Course of Polymyalgia Rheumatica

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Persons with active polymyalgia rheumatica (patients only).~* Signed informed consent and written authorization.~Exclusion Criteria:~* Other inflammatory conditions than polymyalgia rheumatica, including symptoms of giant cell arteritis, e.g. head aches, jaw claudication and visual disturbances.~* Current malignancy or history of malignancy.~* Neuromuscular conditions.~* Infections with systemic impact.~* Uncontrolled diabetes mellitus.~* Uncontrolled hypertension.~* Current tuberculosis or history of tuberculosis.~* Severe heart failure (NYHA class 3 and 4).~* Current use of glucocorticoids, biological drugs, and immunosuppressive drugs.~Exclusion Criteria (controls):~* Polymyalgia rheumatica.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).